An Engineered Cytidine Deaminase for Biocatalytic Production of a Key Intermediate of the Covid-19 Antiviral Molnupiravir코비드-19 항바이러스제 몰누피라비르의 핵심 중간체의 생체촉매 생산을 위한 조작된 시티딘 데아미나제Article Published on 2022-03-092022-09-11 Journal: Journal of the American Chemical Society [Category] COVID19(2023년), SARS, 치료제, [키워드] antiviral drug antiviral drugs approved benefit COVID-19 pandemic cytidine Cytidine deaminase Deaminase enzyme highlight intermediate less molnupiravir nucleoside pandemic Production SARS-CoV-2 selective Treatment [DOI] 10.1021/jacs.1c11048 PMC 바로가기 [Article Type] Article
Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases심장 보호 약물과 COVID-19 치료에 사용되는 약물 간의 약물 상호 작용 위험: 6개 데이터베이스의 증거 기반 검토Review Published on 2022-03-012022-09-11 Journal: Diabetes & metabolic syndrome [Category] SARS, 변종, 신약개발, 치료법, 치료제, [키워드] acting antihypertensive drugs approved Atazanavir Azithromycin cardiovascular system caution Chloroquine close monitoring comorbid condition comorbid conditions Comorbidity concomitant use COVID COVID- 19 treatment COVID-19 COVID-19 infection COVID-19 treatment database Dexamethasone diabetes dosage drug drug interaction drug-drug interaction drugs Effect Effects ENhance Evidence Factor FDA glycemic control group hypertension Hypotension Improving Infection information Interaction interaction effect life Lopinavir Lopinavir/ritonavir Medicine Medscape molnupiravir monoclonal antibodies monoclonal antibody Nirmatrelvir Patient Paxlovid polypharmacy Potential Quality of life Remdesivir resulting review risk Ritonavir therapeutic efficacy therapy treating COVID-19 Treatment worsening [DOI] 10.1016/j.dsx.2022.102451 PMC 바로가기 [Article Type] Review
Establishment of a stable SARS-CoV-2 replicon system for application in high-throughput screening고처리량 스크리닝 적용을 위한 안정적인 SARS-CoV-2 레플리콘 시스템 구축Article Published on 2022-03-012022-09-11 Journal: Antiviral Research [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus Antiviral Antiviral effect antiviral effects Bacterial bacterial artificial chromosome biosafety level Biosafety Level 3 BSL2 BSL3 camostat Cell cell line cell lines cells chromosome compounds condition conditions coronavirus COVID-19 examined exhibited Favipiravir gene encoding In vitro infection inhibited interferon level 3 luciferase luciferase activity molnupiravir Neomycin Novel coronavirus Particles powerful tool produced RdRP RdRp inhibitor Remdesivir Renilla Renilla luciferase replicon reported RNA SARS-coronavirus SARS-coronavirus-2 SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 sgRNA sgRNAs stable cell stable cell line suppressed the SARS-CoV-2 transient transfection transiently transfected Treatment VeroE6 cells Viral proteins viral replication [DOI] 10.1016/j.antiviral.2022.105268 PMC 바로가기 [Article Type] Article
Does ivermectin have a place in the treatment of mild Covid-19?Editorial Published on 2022-03-012022-10-05 Journal: New Microbes and New Infections [Category] 신약개발, 치료법, [키워드] Coronavirus treatment Hospitalization Ivermectin Mild molnupiravir Paxlovid SARS-CoV-2 Treatment [DOI] 10.1016/j.nmni.2022.100985 [Article Type] Editorial
Newer oral antivirals for COVID-19: Are they the real game changer?COVID-19에 대한 최신 경구 항바이러스제: 이것이 진정한 게임 체인저입니까?Article Published on 2022-03-012022-09-11 Journal: Heart & lung : the journal of critical care [Category] SARS, 치료제, [키워드] Abstract Antiviral COVID-19 Evidence Favipiravir molnupiravir omicron [DOI] 10.1016/j.hrtlng.2022.01.011 PMC 바로가기 [Article Type] Article
Oral antivirals for the prevention and treatment of SARS-CoV-2 infectionSARS-CoV-2 감염 예방 및 치료를 위한 경구용 항바이러스제Article Published on 2022-03-012022-09-11 Journal: AIDS reviews [Category] SARS, 변종, 치료제, [키워드] advent Antiviral antiviral therapy antivirals benefit classical combination therapies combination therapy complications COVID-19 COVID-19 disease COVID-19 pandemic Disease progression dissemination Each early treatment Emergency use authorization escape mutant Formulation Infection landscape life-threatening Long-ActingAntivirals manifestation medications Medicine molnupiravir monoclonal antibodies monoclonal antibody Mutagenesis Nirmatrelvir offer oral Oral Remdesivir parenteral administration polymerase Prevent Prophylaxis protease protease inhibitors PROTECT provided reduce regulatory agencies regulatory agency Remdesivir required SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease small molecule treat Treatment Vaccine variant viral illnesses waning immunity [DOI] 10.24875/AIDSRev.22000001 PMC 바로가기 [Article Type] Article
Molnupiravir: First Approval몰누피라비르: 최초 승인Review Published on 2022-03-012022-09-11 Journal: Drugs [Category] SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral approval coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 diagnostic diagnostic test Emergency use authorization inhibit Japan Mild mild to moderate Moderate COVID-19 molnupiravir positive Replication risk factor RNA virus RNA viruses SARS-CoV-2 Treatment USA [DOI] 10.1007/s40265-022-01684-5 PMC 바로가기 [Article Type] Review
Antiviral pills: A potential game-changing therapy against COVID-19항바이러스제: COVID-19에 대한 잠재적인 판도를 바꾸는 치료법Article Published on 2022-03-012022-09-11 Journal: International journal of surgery (London, England) [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] Abstract Antiviral pills COVID-19 management molnupiravir SARS-CoV-2 therapy Vaccines [DOI] 10.1016/j.ijsu.2022.106582 PMC 바로가기 [Article Type] Article
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemicReview Published on 2022-02-242023-07-02 Journal: Future Microbiology [Category] COVID19(2023년), SARS, [키워드] COVID-19 Direct-acting antivirals MK-4482 molnupiravir SARS-CoV-2 [DOI] 10.2217/fmb-2021-0252 PMC 바로가기 [Article Type] Review
COVID-19 updates: NIH outpatient treatment guidelinesArticle Published on 2022-02-212023-07-08 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 Efficacy etesevimab Imdevimab molnupiravir Nirmatrelvir Paxlovid REGEN-COV Remdesivir Ritonavir Sotrovimab Veklury